secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0000950170-24-020146
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen FY23 rev $147.8M (+5% YoY), net loss $284.2M; guides China roxadustat $300-340M
--------------------------------------------------------------------------------

- Full year 2023 total revenue $147.8M, up 5% YoY; net loss $284.2M ($2.92 per share), narrower than $293.7M loss in 2022.
- Roxadustat net sales in China (FibroGen share) $100.9M in FY23, up 22% YoY; total China sales including JDE $284.1M (+36% YoY) driven by 41% volume growth.
- Cash and equivalents $248.1M, with runway into 2026 after $120M annual cost reduction.
- Pipeline: topline data from two pamrevlumab pancreatic cancer trials expected in 2Q 2024; Phase 1 FG-3246 data in mCRPC in 1Q 2024.
- Guidance: FY 2024 FibroGen net product revenue $120-135M; total roxadustat China sales $300-340M; potential CIA approval in China mid-2024 with $10M milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017024020146/0000950170-24-020146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017024020146/fgen-20240226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-020146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer